DTNBP1 is associated with imaging phenotypes in schizophrenia - PubMed (original) (raw)
. 2009 Nov;30(11):3783-94.
doi: 10.1002/hbm.20806.
Philip R Szeszko, Todd Lencz, Roger P Woods, Liberty S Hamilton, Owen Phillips, Delbert Robinson, Katherine E Burdick, Pamela DeRosse, Raju Kucherlapati, Paul M Thompson, Arthur W Toga, Anil K Malhotra, Robert M Bilder
Affiliations
- PMID: 19449336
- PMCID: PMC3176807
- DOI: 10.1002/hbm.20806
Free PMC article
DTNBP1 is associated with imaging phenotypes in schizophrenia
Katherine L Narr et al. Hum Brain Mapp. 2009 Nov.
Free PMC article
Abstract
Dystrobrevin binding protein 1 (DTNBP1) has been identified as putative schizophrenia susceptibility gene, but it remains unknown whether polymorphisms relate to altered cerebral structure. We examined relationships between a previously implicated DTNBP1 risk variant [P1578] and global and segmented brain tissue volumes and regional cortical thickness in schizophrenia (n = 62; 24 risk carriers) and healthy subjects (n = 42; 11 risk carriers), across ethnic groups and within Caucasians. Schizophrenia patients showed similar brain volumes, but significantly reduced brain-size adjusted gray matter and CSF volumes and cortical thinning in a widespread neocortical distribution compared to controls. DTNBP1 risk was found associated with reduced brain volume, but not with tissue sub-compartments. Cortical thickness, which was weakly associated with brain size, showed regional variations in association with genetic risk, although effects were dominated by highly significant genotype by diagnosis interactions over broad areas of cortex. Risk status was found associated with regional cortical thinning in patients, particularly in temporal networks, but with thickness increases in controls. DTNBP1 effects for brain volume and cortical thickness appear driven by different neurobiological processes. Smaller brain volumes observed in risk carriers may relate to previously reported DTNBP1/cognitive function relationships irrespective of diagnosis. Regional cortical thinning in patient, but not in control risk carriers, may suggest that DTNBP1 interacts with other schizophrenia-related risk factors to affect laminar thickness. Alternatively, DTNBP1 may influence neural processes for which individuals with thicker cortex are less vulnerable. Although DTNBP1 relates to cortical thinning in schizophrenia, morphological changes in the disorder are influenced by additional genetic and/or environmental factors.
References
- Mol Psychiatry. 2003 Aug;8(8):717-8 -PubMed
- Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11650-5 -PubMed
- Schizophr Res. 2007 Nov;96(1-3):112-8 -PubMed
- Neuropsychopharmacology. 2005 Sep;30(9):1649-61 -PubMed
- Schizophr Res. 2001 Apr 15;49(1-2):1-52 -PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 MH001760/MH/NIMH NIH HHS/United States
- R01 MH079800/MH/NIMH NIH HHS/United States
- UL1 RR024911/RR/NCRR NIH HHS/United States
- K01 MH065580/MH/NIMH NIH HHS/United States
- R00 MH086756/MH/NIMH NIH HHS/United States
- MH001760/MH/NIMH NIH HHS/United States
- P41 RR013642/RR/NCRR NIH HHS/United States
- U54 RR021813/RR/NCRR NIH HHS/United States
- P41 RR13642/RR/NCRR NIH HHS/United States
- MH079800/MH/NIMH NIH HHS/United States
- R01 MH060374/MH/NIMH NIH HHS/United States
- R01 MH060004/MH/NIMH NIH HHS/United States
- K99 MH086756/MH/NIMH NIH HHS/United States
- K01 MH073990/MH/NIMH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials